✉news ScienceSpace Policy first seen 3 d ago, last 2 d ago, peak #33
Risvutatug Rezetecan Shows Improved PFS in Osteosarcoma at ESMO 2026
Original: ARTEMIS-011 at ESMO 2026: Risvutatug Rezetecan Significantly Improves PFS in Relapsed or Refractory Osteosarcoma
Results from the ARTEMIS-011 trial, presented at ESMO 2026, show that risvutatug rezetecan significantly improves progression-free survival in patients with relapsed or refractory osteosarcoma. The finding is drawing attention from oncologists, as osteosarcoma has few effective options once it returns or stops responding to treatment. If the benefit is confirmed, the drug candidate could become an important new therapy for this rare bone cancer.
Why now: New clinical trial data presented at ESMO 2026 suggest a meaningful advance against a hard-to-treat cancer.
ESMOrisvutatug rezetecanARTEMIS-011osteosarcoma
Rank over time, top of the chart is #1. 5 snapshots from 3 d ago to 2 d ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/3764356